Clinical medicine profile
Maprotiline
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Blood monitoring
- history of epilepsy
- pregnancy and lactation
- history of mania
- close angle glaucoma
- concurrent electroconvulsive therapy
- anaesthesia
- hepatic impairment
- psychosis
- withdraw gradually.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Initially 25-75mg daily in three divided doses or a single dose nocte. [max.150mg].
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Depressive illness
Adverse effects
- Antimuscarinic actions namely: drowsiness
- urinary retention
- dry mouth
- constipation
- blurred vision
- sweating
- hypotensive effect, which may lead to dizziness and syncope.
- Arrhythmias and heart block
- convulsions
- haematological and hepatic reactions
Drug interactions
Open multi-drug checker ↗- A tetracyclic sedating antidepressant.
- Similar to amitripylline.
- Exceptions are that it has less anti-muscarinic effects, more likely to cause rashes and convulsions [at higher doses hence contraindication in patients with history of epilepsy].
Mechanism & disposition
The mechanism of action of is not fully known but may be due to its increasing the synaptic concentration of norepinephrine and/or serotonin in the central nervous system [CNS].
Read complete mechanism
The mechanism of action of is not fully known but may be due to its increasing the synaptic concentration of norepinephrine and/or serotonin in the central nervous system [CNS]. These neurotransmitters are thought to be increased through inhibition of their reuptake by the presynaptic neuronal membrane.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.